Pfizer's Coronavirus Cure Could Reduce Hospitalization Risks by 89% reduce the risks of hospitalization or death after suffering from COVID-19. This became known as a result of a study of the drug, according to the company's website.
It is specified that the studies involved 1.2 thousand COVID-19 patients, in whom the disease could develop in an unfavorable scenario.
< p> A number of volunteers in the study received a placebo. It turned out that those taking the real drug were much less likely to be hospitalized compared to those receiving the placebo. In addition, none of those taking the medicine died. Ten patients died among those taking the placebo.
Pfizer CEO Albert Burla said the drug would help avoid nine out of ten hospitalizations in case of COVID-19 infection.
Formerly a European agency The Medicines Agency (EMA) has responded to reports of a breach in Pfizer's coronavirus vaccine trials. They added that they interact intensively with the US Food and Drug Administration on this issue.